Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04511130 · ClinicalTrials.gov registry record · Phase 2
Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant
A Phase 2 study, sponsored by Marker Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT04511130: Clinical Trial Phase 2 study, sponsored by Marker Therapeutics.
NCT04511130 is a Phase 2 study that was terminated before completion, run by Marker Therapeutics. The registered enrollment target is 92 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04511130, a Phase 2 study, was terminated before completion, sponsored by Marker Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
This study is a Phase 2 multicenter study with a Safety Lead-in evaluating safety and efficacy of MT-401 administration to patients with AML, who have received their first allogeneic HSCT. The dose administered is 50 x 10\^6 cells (flat dosing).
Primary Outcome
Number of participants with MT-401 Dose Limiting Toxicities (DLTs)
Interventions
- DRUG MT-401
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2020-10-14 |
| Est. Completion | 2024-03-01 |
| Phase | Phase 2 |
Why NCT04511130 stopped before completion
NCT04511130 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% lower).
The record links to 0 conditions, and to 1 intervention - of which MT-401 is the first listed.
NCT04511130 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04511130 about?
NCT04511130 is a clinical study titled "Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant". This study is a Phase 2 multicenter study with a Safety Lead-in evaluating safety and efficacy of MT-401 administration to patients with AML, who have received their first allogeneic HSCT. The dose administered is 50 x 10\^6 cells (flat dosing).
What is the current status of trial NCT04511130?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2020-10-14. Estimated completion is 2024-03-01.
What interventions are being tested in trial NCT04511130?
The interventions under investigation include: MT-401 (DRUG).
Who is sponsoring clinical trial NCT04511130?
This trial is sponsored by Marker Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04511130's enrollment target sits among peer trials
92 767th of 2000 higher than 1,230 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI